当前位置：
X-MOL 学术
›
Bipolar Disord.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Use of botulinum toxin A for depression symptoms in patients with treatment-resistant bipolar illness: A case series
Bipolar Disorders ( IF 5.4 ) Pub Date : 2023-11-05 , DOI: 10.1111/bdi.13389 Ali A Farooqui 1, 2 , Jessica M Fulkerson 3 , Rif S El-Mallakh 4
中文翻译：
使用 A 型肉毒杆菌毒素治疗难治性双相情感障碍患者的抑郁症状：病例系列
更新日期：2023-11-05
Bipolar Disorders ( IF 5.4 ) Pub Date : 2023-11-05 , DOI: 10.1111/bdi.13389 Ali A Farooqui 1, 2 , Jessica M Fulkerson 3 , Rif S El-Mallakh 4
Affiliation
CONFLICT OF INTEREST STATEMENT
Dr. El-Mallakh has research funding from Sunovion and is on the speakers' bureau of Axsome, Intracellular, Janssen, Lundbeck, Myriad, Noven, Otsuka, and Teva. Dr. Farooqui is on the speaker's bureau of Abbvie and BioXcel.
中文翻译：
使用 A 型肉毒杆菌毒素治疗难治性双相情感障碍患者的抑郁症状：病例系列
利益冲突声明
El-Mallakh 博士获得了 Sunovion 的研究资助，并且是 Axsome、Intracellular、Janssen、Lundbeck、Myriad、Noven、Otsuka 和 Teva 的演讲局成员。Farooqui 博士是 Abbvie 和 BioXcel 发言人办公室的成员。
京公网安备 11010802027423号